Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Lymphoma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lymphoma. Browse Lymphoma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 23, 2026 Report an issue

ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1357
Shown on this page
12
Current sort
Recently updated
Condition scope
Lymphoma
Additional filters apply within this condition.
The trial list below is retrieved from the live ClinicalTrials.gov search API for Lymphoma. Results on this page are currently sorted by Recently updated.

How Lymphoma studies are organized in the registry

Lymphoma records divide between Hodgkin and non-Hodgkin disease, and non-Hodgkin studies usually name the histology directly — diffuse large B-cell (DLBCL), follicular, mantle cell, and others. Subtype abbreviations are the most reliable narrowing terms because they appear in titles and condition fields verbatim.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Lymphoma. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 1,357 matching trials for Lymphoma.
Live ClinicalTrials.gov results.
Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting No phase listed Observational

Clonal Evolution in Follicular Lymphoma

NCT03190928
Conditions
Follicular Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
49
States / cities
Fresno, California • Irvine, California • Los Alamitos, California + 42 more
Conditions
B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma
Interventions
BGB-16673
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 26 more
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride, pharmacogenomic studies, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Kami Maddocks, MD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Interventions
None - Observational Study
Other
Lead sponsor
Tempus AI
Industry
Eligibility
0 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
9
States / cities
Iowa City, Iowa • Bethesda, Maryland • St Louis, Missouri + 6 more
Conditions
B-cell Malignancies
Interventions
AZD5492
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 6 more
Conditions
Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions
Xanamem, Placebo
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
Conditions
Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
11
States / cities
Springdale, Arkansas • La Jolla, California • Torrance, California + 8 more
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Epcoritamab, Magnetic Resonance Imaging, Polatuzumab Vedotin, Positron Emission Tomography, Prednisone, Rituximab
Procedure · Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
70 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Conditions
B-Cell Non-Hodgkins Lymphoma
Interventions
Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
33
States / cities
Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more
Conditions
Untreated Follicular Lymphoma
Interventions
Surovatamig, R-CHOP, R-CVP, BR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
55
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 49 more
Conditions
Cognitive Dysfunction, Dementia, Mild
Interventions
FitMi AD, Conventional exercise program
Device · Other
Lead sponsor
Flint Rehabilitation Devices, LLC
Industry
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Downey, California

About this Lymphoma clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lymphoma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lymphoma.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Lymphoma.